Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care
Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.
Pharma & Biotech
Pharma & Biotech
Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?
Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.
Pharma & Biotech
Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Pharma & Biotech
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
Pharma & Biotech
What BridgeBio Pharma, Inc.’s latest data signals for the future of targeted endocrine therapies
Explore how BridgeBio Pharma, Inc.’s Phase 3 CALIBRATE data could transform ADH1 treatment and reshape rare endocrine care. Read more now.
Pharma & Biotech
Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences
Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.
Pharma & Biotech
Innovent’s mazdutide earns Nature spotlight: Are dual GCG/GLP-1 agonists set to reshape diabetes and obesity care?
Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese